Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer.

Stephanie L Wethington Payal Deepak Shah Lainie P Martin Janos L Tanyi Nawar A Latif Mark A Morgan Drew A Torigian Diego Rodriguez Simon A Smith Emma Dean Susan M Domchek Ronny Drapkin Ie-Ming Shih Eric J Brown Wei-Ting Hwang Deborah K Armstrong Stephanie Gaillard Robert Giuntoli Fiona Simpkins

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Combination olaparib and ceralasertib is tolerable and shows activity in HR-deficient platinum-sensitive recurrent HGSOC that benefited and then progressed with PARPi as the penultimate regimen. These data suggest that ceralasertib re-sensitizes PARPi resistant HGSOCs to olaparib, warranting further investigation.

Keyphrases

dna repair
dna damage
dna damage response
clinical trial
study protocol
electronic health record
phase ii
induced apoptosis
phase iii
big data
deep learning
machine learning
endoplasmic reticulum stress